Experimental combo targets hard-to-treat cancers in early trial
NCT ID NCT05147272
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-phase study tested a new drug called RP-6306 combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could shrink tumors. The study was terminated early, but results may still help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
# 1004, Memorial Sloan Kettering Cancer Institute
New York, New York, 10065, United States
-
# 1008, Columbia University
New York, New York, 10032, United States
-
# 1010, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
# 1016, Mayo Clinic
Rochester, Minnesota, 55902, United States
-
# 1017, Mayo Clinic
Jacksonville, Florida, 32224, United States
-
# 1018, Mayo Clinic
Phoenix, Arizona, 85054, United States
-
# 1019, UCLA, Westwood Cancer Center
Los Angeles, California, 90095, United States
-
# 1022, Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
# 1023, START Midwest
Grand Rapids, Michigan, 49546, United States
-
# 2001, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
# 3003, Sarah Cannon Research Institute
London, United Kingdom
Conditions
Explore the condition pages connected to this study.